Advertisement
Advertisement
U.S. markets open in 3 hours 53 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Verve Therapeutics, Inc. (VERV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
16.90+0.72 (+4.45%)
At close: 04:00PM EDT
17.00 +0.10 (+0.59%)
Pre-Market: 04:39AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close16.18
Open16.35
Bid0.00 x 1100
Ask0.00 x 1000
Day's Range15.06 - 16.92
52 Week Range10.70 - 78.00
Volume1,649,138
Avg. Volume692,983
Market Cap822.378M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.58
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est53.83
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for VERV

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Verve Therapeutics, Inc.
    Analyst Report: Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
    Rating
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • GlobeNewswire

    Verve Therapeutics Appoints Experienced Biotechnology Executive, Alexander G. “Bo” Cumbo, to its Board of Directors

    CAMBRIDGE, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Alexander G. “Bo” Cumbo, chief executive officer and president of AavantiBio, Inc., has joined the company’s board of directors. “Bo is a highly experienced industry executive with a well-established track record of leading pharmaceutical and life sciences companies through c

  • GlobeNewswire

    Verve Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

    CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in a fireside chat during the 2022 Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 1:00 p.m. ET in NYC. A live webcast will be available in the investor section of the company's web

  • Insider Monkey

    10 Most Shorted Stocks to Watch

    In this article, we discuss the 10 most shorted stocks to watch today. To take a look at some more stocks, go directly to the 5 Most Shorted Stocks to Watch. The US stock market has been in a correction mode as the S&P 500 Index and the Dow 30 Index have lost more than […]

Advertisement
Advertisement